000012540 001__ 12540
000012540 005__ 20240711085559.0
000012540 0247_ $$2DOI$$a10.1149/1.3476296
000012540 0247_ $$2WOS$$aWOS:000281306900040
000012540 0247_ $$2ISSN$$a0013-4651
000012540 0247_ $$2ISSN$$a0096-4743
000012540 0247_ $$2ISSN$$a0096-4786
000012540 0247_ $$2ISSN$$a1945-7111
000012540 037__ $$aPreJuSER-12540
000012540 041__ $$aeng
000012540 082__ $$a540
000012540 084__ $$2WoS$$aElectrochemistry
000012540 084__ $$2WoS$$aMaterials Science, Coatings & Films
000012540 1001_ $$0P:(DE-HGF)0$$aFonseca, F.C.$$b0
000012540 245__ $$aTemperature and Bias Effects on Sputtered Ceria Diffusion Barriers for Solid  Oxide Fuel Cells
000012540 260__ $$aPennington, NJ$$bElectrochemical Society$$c2010
000012540 300__ $$aB1515 - B1519
000012540 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000012540 3367_ $$2DataCite$$aOutput Types/Journal article
000012540 3367_ $$00$$2EndNote$$aJournal Article
000012540 3367_ $$2BibTeX$$aARTICLE
000012540 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000012540 3367_ $$2DRIVER$$aarticle
000012540 440_0 $$03889$$aJournal of the Electrochemical Society$$v157$$x0013-4651$$y10
000012540 500__ $$aF.C.F. is thankful for the Brazilian agencies FAPESP (2007/08686-8) and CNPq (306422/2007-7). Thanks also to F. Vondahlen for helping us with PVD depositions and W. Herzhof and K. Portulidou for sample supplying/cathode depositions.
000012540 520__ $$aThis open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests.Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had > or = 50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%).In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults.
000012540 536__ $$0G:(DE-Juel1)FUEK402$$2G:(DE-HGF)$$aRationelle Energieumwandlung$$cP12$$x0
000012540 536__ $$0G:(DE-Juel1)SOFC-20140602$$aSOFC - Solid Oxide Fuel Cell (SOFC-20140602)$$cSOFC-20140602$$fSOFC$$x1
000012540 588__ $$aDataset connected to Web of Science, Pubmed
000012540 650_7 $$2WoSType$$aJ
000012540 7001_ $$0P:(DE-Juel1)129580$$aUhlenbruck, S.$$b1$$uFZJ
000012540 7001_ $$0P:(DE-Juel1)VDB86736$$aNédélec, R.$$b2$$uFZJ
000012540 7001_ $$0P:(DE-Juel1)129662$$aSebold, D.$$b3$$uFZJ
000012540 7001_ $$0P:(DE-Juel1)129594$$aBuchkremer, H. P.$$b4$$uFZJ
000012540 773__ $$0PERI:(DE-600)2002179-3$$a10.1149/1.3476296$$gVol. 157, p. B1515 - B1519$$pB1515 - B1519$$q157<B1515 - B1519$$tJournal of the Electrochemical Society$$v157$$x0013-4651$$y2010
000012540 8567_ $$uhttp://dx.doi.org/10.1149/1.3476296
000012540 8564_ $$uhttps://juser.fz-juelich.de/record/12540/files/FZJ-12540_PV.pdf$$yRestricted$$zPublished final document.
000012540 909CO $$ooai:juser.fz-juelich.de:12540$$pVDB
000012540 915__ $$0StatID:(DE-HGF)0010$$aJCR/ISI refereed
000012540 9141_ $$y2010
000012540 9131_ $$0G:(DE-Juel1)FUEK402$$aDE-HGF$$bEnergie$$kP12$$lRationelle Energieumwandlung$$vRationelle Energieumwandlung$$x0
000012540 9132_ $$0G:(DE-HGF)POF3-135$$1G:(DE-HGF)POF3-130$$2G:(DE-HGF)POF3-100$$aDE-HGF$$bForschungsbereich Energie$$lSpeicher und vernetzte Infrastrukturen$$vFuel Cells$$x0
000012540 9201_ $$0I:(DE-Juel1)IEK-1-20101013$$gIEK$$kIEK-1$$lWerkstoffsynthese und Herstellverfahren$$x0
000012540 970__ $$aVDB:(DE-Juel1)124203
000012540 980__ $$aVDB
000012540 980__ $$aConvertedRecord
000012540 980__ $$ajournal
000012540 980__ $$aI:(DE-Juel1)IEK-1-20101013
000012540 980__ $$aUNRESTRICTED
000012540 981__ $$aI:(DE-Juel1)IMD-2-20101013